| 摘要 |
The pharmaceutical prod. contains cpd. A - a blocker of the brief leaving current of cardiac potassium, (as defined by Dukes and Morad Am. J. Phsiol. 257: H1746-H1749, (1989)) and cpd. B - a specific blocker of the rectifier channel of deferred cardiac potassium, (as defined by Follmer and Colatsky, Circulation 82:288 - 293, (1990)), the two cpds. being administered simultaneously or sequentially. Cpd. A is pref. 3,7-di(cyclo propylmethyl)-9,9-tetramethylene- 3,7-diazabicyclo-(3.3.1)-nonane, or one of its salts and solvates, in US 4 550 112. Cpd. B is pref. 1-(2-(6-methyl-2-pyridyl) ethyl)- 4-(4-methyl sulphonyl amino benzoyl)-piperidine or one of its salts and solvates, described in EP 235752. USE/ADVANTAGE - The cpds. act synergistically to prevent arrhythmias, esp. ventricular arrhythmias. The cpds. may be given by any route - orally, parenterally, or topically - the unit dose of each being 0.1-500 mg, pref. 2 - 50 mg. The daily dosage is most often in the range 50-2000 mg for an adult. At these doses the cpd. do not show any toxic effect.
|
